The Filing Desk

Monte Rosa Therapeutics vs Xencor

Monte Rosa Therapeutics GLUE · Xencor XNCR · Biotechnology

Xencor reported revenue of $126 million in fiscal 2025, about the same as Monte Rosa Therapeutics' $124 million in fiscal 2025. Monte Rosa Therapeutics' revenue grew 63.5% in its latest year, and Xencor's grew 13.7%. Monte Rosa Therapeutics had an operating margin of -43.8%, against -141.3% at Xencor. Free cash flow was −$28 million at Monte Rosa Therapeutics and −$138 million at Xencor.

Side by side

Monte Rosa TherapeuticsXencor
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$124M$126M
Revenue growth63.5%13.7%
Revenue growth a year, last 5 years—0.5%
Gross margin——
Operating margin−43.8%−141.3%
Net margin−31.2%−73.2%
Free cash flow−$28M−$138M
Free cash flow margin−22.2%−110.1%
Return on capital—−19.9%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count12.4%14.1%
Last close$9.37$37.09
P/E at the last close——
Insider trades, last 12 months—sold $7.4 million
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Monte Rosa TherapeuticsXencor
Operating margin
Percent of revenue
Monte Rosa TherapeuticsXencor
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Monte Rosa TherapeuticsXencor

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Monte Rosa Therapeutics and Xencor pages.